Acid-suppressive medications in the first year of life and risk of childhood asthma: a population-based birth cohort study.

Asthma is the most frequent immune-mediated chronic condition among children, and is associated with genetic risk factors as well as specific prenatal and early-life exposures [1]. Gastroesophageal reflux disease (GERD) is a common paediatric condition [2], associated with bronchospasms in infants and has been considered a possible risk factor for the development of asthma, although the results are inconsistent [2, 3]. The treatment for GERD is based on acid-suppressive medications, mainly proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) [4]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Barbiellini Amidei has nothing to disclose. Conflict of interest: Dr. Comoretto has nothing to disclose. Conflict of interest: Dr. Zanier has nothing to disclose. Conflict of interest: Dr. Dona' has nothing to disclose. Conflict of interest: Dr. Cantarutti has nothing to disclose. Conflict of interest: Dr. Canova has nothing to disclose.